💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Trazodone

CHEMBL621 Phase 4 Одобрено Small molecule
Half-Life
5-9 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
371.9 g/mol
LogP
2.8
Phase
4

This antidepressant medication is prescribed for depression and is widely used off-label to treat insomnia because of its sedating properties. It works primarily by blocking serotonin receptors and inhibiting serotonin reuptake in the brain, with relatively little effect on other neurotransmitters. Unlike many sleep aids, it is generally not habit-forming.

Молекулярная масса

371,8640 g/mol

LogP

2,80

TPSA

42,40 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Cardiovascular Disease Psychiatry Respiratory Disease Pain Management Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Generalized Anxiety Disorder Insomnia Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Hypertension Major Depressive Disorder Chronic Pain

Классы препаратов

N — N - Nervous System

Механизм действия

Serotonin antagonist and reuptake inhibitor (SARI).

Pharmacokinetics (PK)

Half-Life 5-9 hours

Pharmacodynamics (PD)

Механизм

Serotonin antagonist and reuptake inhibitor (SARI).

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12

                

                

                
                

                    
InChI

                    
InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H22ClN5O

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
Вращаемые Связи

                        
5

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
26

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HRH1 (Histamine H1 Receptor)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            SLC6A4 (Serotonin Transporter)
                            Inhibitor
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Trazodone + Sertraline
                            
                        

                        
                        
Sertraline combined with trazodone may increase the risk of serotonin syndrome due to additive serotonergic effects.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Trazodone + Fluoxetine
                            
                        

                        
                        
Fluoxetine inhibits CYP2D6-mediated metabolism of trazodone, significantly increasing trazodone plasma levels and serotonin syndrome risk.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This antidepressant medication is prescribed for depression and is widely used off-label to treat insomnia because of its sedating properties. It works primarily by blocking serotonin receptors and inhibiting serotonin reuptake in the brain, with relatively little effect on other neurotransmitters. Unlike many sleep aids, it is generally not habit-forming.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Serotonin antagonist and reuptake inhibitor (SARI).

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Trazodone: Half-life: 5-9 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Trazodone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL621.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5533.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.